Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic appears in 12 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Clinical trials
12 shownDrugs studied in this sponsor's trials
0 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
No mapped drug interventions are published for this sponsor's trials. This does not mean the studies contain no drug interventions: some registry names have not been mapped to RxNorm.
Sponsor roles
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.